Quantcast

Latest Haemophilia Stories

2014-07-07 16:23:47

First Recombinant Treatment Approved in US for Patients With GT With Refractoriness to Platelet Transfusions, With or Without Antibodies to Platelets PLAINSBORO, N.J., July 7, 2014 /PRNewswire/ -- Novo Nordisk today announced the US Food and Drug Administration (FDA) has approved NovoSeven(®) RT (Coagulation Factor VIIa [Recombinant]) as the first recombinant treatment for bleeding episodes and perioperative management in patients with Glanzmann's Thrombasthenia (GT) with refractoriness to...

2014-06-26 23:09:03

The National Hemophilia Foundation (NHF) with the guidance of its Medical and Scientific Advisory Council (MASAC), today announced that it is initiating a multi-year project to develop evidence-based clinical practice guidelines (CPGs) to ensure that patients with hemophilia in the United States and elsewhere receive high quality care. New York, NY (PRWEB) June 26, 2014 The National Hemophilia Foundation(NHF) with the guidance of its Medical and Scientific Advisory Council (MASAC), today...

2014-06-23 08:27:25

LEVERKUSEN, Germany, June 23, 2014 /PRNewswire/ -- Bayer HealthCare (Bayer) and Dimension Therapeutics, a company focused on developing novel adeno-associated virus (AAV) gene therapy treatments for rare diseases, have entered into a collaboration for the development and commercialization of a novel gene therapy for the treatment of hemophilia A. "Bayer is a worldwide leader in the treatment of hemophilia A and we are highly committed to advancing innovative treatment options for...

2014-06-11 23:08:19

Redesigned Website Positions NHF as Global Leader of Information to the Bleeding Disorders Community New York, NY (PRWEB) June 11, 2014 The National Hemophilia Foundation (NHF), the global leader of information to the bleeding disorders community, today announced the launch of its newly redesigned hemophilia.org corporate website. The redesigned website has improved navigation and search functions, streaming social media content, updated information on programs, services and events for...

2014-06-10 23:02:32

Transparency Market Research added a new report "Hemophilia Treatment Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019" to its report store. Browse the full report: http://www.transparencymarketresearch.com/hemophilia-treatment-market.html. Albany, New York (PRWEB) June 10, 2014 Hemophilia is a group of hereditary genetic disorders that affects the body’s ability to control blood coagulation. The bleeding can be internal or external,...

2014-06-02 23:01:38

This month Chris Bombardier will attempt to be the first person with hemophilia to scale Mt. McKinley, the highest peak in North America and the fourth mountain in his Seven Summits Quest. Georgetown, MA (PRWEB) June 02, 2014 Mt. Kilimanjaro. Mt. Elbrus. Mt. Aconcagua. What do these mountains have in common? Each is the highest peak on their respective continent: Africa, Europe and South America, and each has been summited by Chris Bombardier, a 28-year-old from Denver, Colorado whose...

2014-05-16 16:24:47

Five U.S. Researchers among Recipients of Prestigious Award WHIPPANY, N.J., May 16, 2014 /PRNewswire/ -- Bayer HealthCare announced today the 2014 recipients of the Bayer Hemophilia Awards Program (BHAP), a unique initiative dedicated to supporting innovative research and educational initiatives that benefit people with hemophilia around the world. American researchers and clinicians represented the largest group of winners from one country, with five individuals receiving awards. This year,...

2014-05-12 08:31:01

- Kogenate® FS antihemophilic factor (recombinant) approved for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults with hemophilia A WHIPPANY, N.J., May 12, 2014 /PRNewswire/ -- Bayer HealthCare announced today that the U.S. Food and Drug Administration (FDA) has approved a new indication for Bayer's Kogenate® FS antihemophilic factor VIII (recombinant), for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults...

2014-05-11 20:21:16

Data showing improved pharmacokinetic profile to be presented at World Federation of Hemophilia Congress MELBOURNE, Australia, May 11, 2014 /PRNewswire/ -- Interim Phase II/III and III findings presented today by CSL Behring at the World Federation of Hemophilia (WFH) 2014 Congress demonstrate an improved pharmacokinetic (PK) profile of recombinant fusion protein linking coagulation factor IX with recombinant albumin (rIX-FP) among hemophilia B patients of all age groups. These...

2014-05-09 12:25:57

-- Leading-edge science at the core of $250 million expansion to drive long-term growth in promising bleeding disorders portfolio KING OF PRUSSIA, Pa., May 9, 2014 /PRNewswire/ -- CSL Limited (ASX:CSL), parent company of CSL Behring which is based in King of Prussia, PA, today opened the CSL Behring Biotechnology Manufacturing Facility in Melbourne, Australia. The new facility, located adjacent to the site's manufacturing plant for plasma products, is the centerpiece of CSL's...


Word of the Day
snash
  • To talk saucily.
  • Insolent, opprobrious language; impertinent abuse.
This word is Scots in origin and probably imitative.